These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 32098121)
1. Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer. Casas-Arozamena C; Díaz E; Moiola CP; Alonso-Alconada L; Ferreirós A; Abalo A; Gil CL; Oltra SS; de Santiago J; Cabrera S; Sampayo V; Bouso M; Arias E; Cueva J; Colas E; Vilar A; Gil-Moreno A; Abal M; Moreno-Bueno G; Muinelo-Romay L J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32098121 [TBL] [Abstract][Full Text] [Related]
2. Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application. Casas-Arozamena C; Vilar A; Cueva J; Arias E; Sampayo V; Diaz E; Oltra SS; Moiola CP; Cabrera S; Cortegoso A; Curiel T; Abalo A; Pamies Serrano M; Domingo S; Padilla-Iserte P; Arnaez de la Cruz M; Hernández A; García-Pineda V; Ruiz-Bañobre J; López R; Matias-Guiu X; Colás E; Gil-Moreno A; Abal M; Moreno-Bueno G; Muinelo-Romay L J Exp Clin Cancer Res; 2024 Sep; 43(1):264. PubMed ID: 39304963 [TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy: current technology and clinical applications. Nikanjam M; Kato S; Kurzrock R J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847 [TBL] [Abstract][Full Text] [Related]
4. Noninvasive detection of microsatellite instability in patients with endometrial cancer. Casas-Arozamena C; Moiola CP; Vilar A; Bouso M; Cueva J; Cabrera S; Sampayo V; Arias E; Abalo A; García Á; Lago-Lestón RM; Oltra S; Díaz E; Ruiz-Bañobre J; López-López R; Moreno-Bueno G; Gil-Moreno A; Colás E; Abal M; Muinelo-Romay L Int J Cancer; 2023 May; 152(10):2206-2217. PubMed ID: 36650670 [TBL] [Abstract][Full Text] [Related]
5. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761 [TBL] [Abstract][Full Text] [Related]
6. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599 [TBL] [Abstract][Full Text] [Related]
7. Next generation sequencing of glioblastoma circulating tumor cells: non-invasive solution for disease monitoring. Kolostova K; Pospisilova E; Pavlickova V; Bartos R; Sames M; Pawlak I; Bobek V Am J Transl Res; 2021; 13(5):4489-4499. PubMed ID: 34150029 [TBL] [Abstract][Full Text] [Related]
8. Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer. Chen Q; Zhang ZH; Wang S; Lang JH Onco Targets Ther; 2019; 12():11517-11530. PubMed ID: 31920340 [TBL] [Abstract][Full Text] [Related]
9. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA. Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336 [TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing for tumor mutation quantification using liquid biopsies. Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650 [TBL] [Abstract][Full Text] [Related]
11. Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer. Markou AN; Londra D; Stergiopoulou D; Vamvakaris I; Potaris K; Pateras IS; Kotsakis A; Georgoulias V; Lianidou E Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980762 [TBL] [Abstract][Full Text] [Related]
13. Using circulating cell-free DNA to monitor personalized cancer therapy. Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575 [TBL] [Abstract][Full Text] [Related]
14. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing. Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823 [TBL] [Abstract][Full Text] [Related]
15. High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer. Ashley CW; Selenica P; Patel J; Wu M; Nincevic J; Lakhman Y; Zhou Q; Shah RH; Berger MF; Da Cruz Paula A; Brown DN; Marra A; Iasonos A; Momeni-Boroujeni A; Alektiar KM; Long Roche K; Zivanovic O; Mueller JJ; Zamarin D; Broach VA; Sonoda Y; Leitao MM; Friedman CF; Jewell E; Reis-Filho JS; Ellenson LH; Aghajanian C; Abu-Rustum NR; Cadoo K; Weigelt B Clin Cancer Res; 2023 Jan; 29(2):410-421. PubMed ID: 36007103 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551 [TBL] [Abstract][Full Text] [Related]
17. Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer. Keup C; Storbeck M; Hauch S; Hahn P; Sprenger-Haussels M; Tewes M; Mach P; Hoffmann O; Kimmig R; Kasimir-Bauer S Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30781720 [TBL] [Abstract][Full Text] [Related]
18. Improving the Management of Endometrial Cancer Patients through the Use of Liquid Biopsy Analyses: A Case Report. Casas-Arozamena C; Cortegoso A; Piñeiro-Perez R; Abalo A; Arias E; Sampayo V; Vilar A; Bouso M; Diaz E; Moreno-Bueno G; López-López R; Muinelo-Romay L; Abal M; Cueva J Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955673 [TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer. Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036 [TBL] [Abstract][Full Text] [Related]
20. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. Shields MD; Chen K; Dutcher G; Patel I; Pellini B Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]